About: Microarray Analysis of Gene Expression of Cancer to Guide the Use of Chemotherapeutics

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Microarray Analysis of Gene Expression of Cancer to Guide the Use of Chemotherapeutics Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Microarray Analysis of Gene Expression of Cancer to Guide the Use of Chemotherapeutics
Creator	Chao, Angel Wang, Tzu-Hao
Source	Elsevier; Medline; PMC
abstract	Summary The beauty of microarray analysis of gene expression (MAGE) is that it can be used to discover some genes that were previously thought to be unrelated to a physiologic or pathologic event. During the period from 1999 to 2007, applications of MAGE in cancer investigation have shifted from molecular profiling, identifying previously undiscovered cancer types, predicting outcomes of cancer patients, revealing metastasis signatures of solid tumors, to guiding the use of therapeutics. The roles of cancer genomic signatures have evolved through three phases. In the first phase, genomic signatures were described in stored cancer specimens and dubbed as molecular portraits of cancer. When gene expression profiles were carefully correlated with sufficient clinical information of cancer patients, new subgroups of cancers with distinct outcomes were revealed. In studies of the second phase, validation of cancer signatures was emphasized and commonly performed with independent groups of cancer specimens or independent data set. In the third phase, cancer genomic signatures have been further expanded beyond depicting the molecular portrait of cancer to predicting patient outcomes and guiding the use of cancer therapeutics. Cancer genomic signatures have become an essential part of a new generation of cancer clinical trials. It is advocated that, in future clinical trials of cancer therapy, the cancer specimens of each participant should be tested for currently available predictor genomic signatures, so that the most effective treatment with the least adverse effects for each patient can be identified. Then, participants can be triaged to an appropriate study group.
has issue date	2007-09-30(xsd:dateTime)
bibo:doi	10.1016/s1028-4559(08)60024-8
bibo:pmid	17962100
has license	els-covid
sha1sum (hex)	bb0ce67ce8fdfac2b785a03b2527fb8d5690496c
schema:url	https://doi.org/10.1016/s1028-4559%2808%2960024-8
resource representing a document's title	Microarray Analysis of Gene Expression of Cancer to Guide the Use of Chemotherapeutics
has PubMed Central identifier	PMC7129596
has PubMed identifier	17962100
schema:publication	Taiwanese Journal of Obstetrics and Gynecology
resource representing a document's body	covid:bb0ce67ce8fdfac2b785a03b2527fb8d5690496c#body_text
is schema:about of	named entity 'clinical trials' named entity 'participant' named entity 'During' named entity 'revealed' named entity 'identifying' named entity 'phase' named entity 'cancer' named entity 'dubbed' named entity 'PREDICTING PATIENT OUTCOMES' named entity 'USE OF' named entity 'THOUGHT' named entity 'AVAILABLE' named entity 'CHEMOTHERAPEUTICS' named entity 'INDEPENDENT' named entity 'ESSENTIAL' named entity 'OF EACH' named entity 'SHIFTED' named entity 'GENOMIC' named entity 'CANCER THERAPEUTICS' named entity 'CURRENTLY' named entity 'ROLES' named entity 'METASTASIS' named entity 'USE OF' named entity 'CORRELATED' named entity 'MOLECULAR' named entity 'HAVE' named entity 'THERAPEUTICS' named entity 'SUFFICIENT' named entity 'TESTED FOR' named entity 'BEAUTY' named entity 'PREDICTOR' named entity 'CANCERS' named entity 'PARTICIPANT' named entity 'GUIDING' named entity 'PARTICIPANTS' named entity 'NEW' named entity 'SECOND PHASE' named entity 'CLINICAL TRIALS' named entity 'VALIDATION' named entity 'PREVIOUSLY' named entity 'SPECIMENS' named entity 'PHYSIOLOGIC' named entity 'PREDICTING' named entity 'PHASE' named entity 'TO GUIDE' named entity 'GENE EXPRESSION' named entity 'EFFECTIVE' named entity 'IDENTIFIED' named entity 'BEYOND' named entity 'SIGNATURES' named entity 'MICROARRAY ANALYSIS' named entity 'CANCER' named entity 'DATA SET' named entity 'STORED' named entity 'ADVERSE EFFECTS' named entity 'DISCOVER' named entity 'MOLECULAR PROFILING' named entity 'GENERATION' named entity 'PORTRAIT' named entity '283' named entity 'TYPES' named entity 'APPLICATIONS' named entity 'GROUPS' named entity 'PERFORMED' named entity 'OUTCOMES' named entity 'EVENT' named entity 'GENES' named entity 'MICROARRAY ANALYSIS' named entity 'REVEALING' named entity 'STUDY GROUP' named entity 'DISTINCT' named entity 'PHASES' named entity 'INVESTIGATION' named entity 'REVEALED' named entity 'MAGE' named entity 'GENE EXPRESSION PROFILES' named entity 'PATIENTS' named entity 'GENE EXPRESSION' named entity 'CLINICAL INFORMATION' named entity 'TREATMENT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software